CORPORATE ANNOUNCEMENTDrug Manufacturers - Specialty & Generic

Novartis India makes a corporate announcement

Novartis IndiaNOVARTIND

TL;DR

The acquisition of the 70.68% controlling stake in Novartis India Limited (NIL) by the ChrysCapital-led consortium for Rs 1,445.89 Crores implies a 100% equity valuation of Rs 2,045.68 Crores (derived from Rs 1,445.89 Crores divided by 70.68%), representing a blended price of Rs 828.56 per share (derived from Rs 1,445.89 Crores divided by 1,74,50,680 shares). Benchmarked against pre-transaction announcement earnings (Q3 FY26 trailing twelve-month PAT of Rs 97.23 Crores), the acquisition implies a TTM P/E multiple of 21.04x and a P/B multiple of 2.64x relative to Q3 FY26 book value of Rs 775.07 Crores.

Based on the Public Announcement filed with the exchanges, what is the implied valuation multiple of the 70.68% stake acquisition compared to Novartis India’s trailing twelve-month (TTM) earnings and current book value?

Valuation Verdict

The acquisition of the 70.68% controlling stake in Novartis India Limited (NIL) by the ChrysCapital-led consortium for Rs 1,445.89 Crores [1] implies a 100% equity valuation of Rs 2,045.68 Crores (derived from Rs 1,445.89 Crores divided by 70.68%), representing a blended price of Rs 828.56 per share (derived from Rs 1,445.89 Crores divided by 1,74,50,680 shares).

Benchmarked against pre-transaction announcement earnings (Q3 FY26 trailing twelve-month PAT of Rs 97.23 Crores [2]), the acquisition implies a TTM P/E multiple of 21.04x and a P/B multiple of 2.64x relative to Q3 FY26 book value of Rs 775.07 Crores [3].

If evaluated at the mandatory Open Offer / SPA Offshore price of Rs 860.64 per share [4] (which values 100% equity at Rs 2,124.99 Crores, derived from 2,46,90,797 total shares [1] times Rs 860.64), the deal implies a TTM P/E multiple of 21.86x and a P/B multiple of 2.74x.

---

Valuation Multiple Matrix

---

Transaction Structure & Financial Evidence

  • Total Share Capital: Novartis India Limited's total voting equity share capital consists of 2,46,90,797 equity shares of face value Rs 5 each [1].
  • Controlling Stake Acquired: The Acquirers (WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners) entered into a Share Purchase Agreement (SPA) on February 19, 2026, to acquire 1,74,50,680 equity shares (70.68%) from Novartis AG [5].
  • Tiered Acquisition Pricing Structure:
  • WaveRise Investments (Acquirer 1): Acquired 1,39,38,382 shares (56.45%) at Rs 860.64 per share (SPA Offshore Price) [5].
  • ChrysCapital Fund X (Acquirer 2): Acquired 25,47,189 shares (10.32%) at Rs 701.25 per share (SPA Onshore Price 1) [5].
  • Two Infinity Partners (Acquirer 3): Acquired 9,65,109 shares (3.91%) at Rs 701.25 per share (SPA Onshore Price 2) [5].
  • Mandatory Open Offer Terms: The acquisition triggered a mandatory Open Offer under SEBI (SAST) Regulations for an additional 26% stake (64,19,608 shares) at an Offer Price of Rs 860.64 per share, totaling up to Rs 552.50 Crores in cash [1].

---

Financial Benchmarks Baseline

  • Pre-Announcement TTM PAT (Q3 FY26 ended Dec 31, 2025): Standalone TTM PAT was Rs 97.23 Crores [2], yielding a TTM EPS of Rs 39.39 per share [6].
  • Pre-Announcement Book Value (Q3 FY26 ended Dec 31, 2025): Standalone Total Equity stood at Rs 775.07 Crores [3], translating to a Book Value per share of Rs 62.81 [7].
  • Full Year FY26 Reported Actuals (ended Mar 31, 2026): Standalone TTM PAT closed at Rs 93.18 Crores [2] (TTM EPS of Rs 37.75 [6]), while Total Equity expanded to Rs 817.83 Crores [3] (Book Value per share of Rs 66.27 [7]).

---

Key Takeaways

  • Substantial Valuation Discount to Secondary Market Trading: The deal multiple of ~21.0x-21.9x TTM P/E sits at a steep discount to prevailing market prices at the time of regulatory review. On June 04, 2026, NIL shares traded at Rs 1,351.20 [8] (implying a market P/E of ~34.3x on Q3 FY26 TTM EPS of Rs 39.39, derived). This pricing mismatch resulted in public shareholders tendering only 40 shares in the 26% Open Offer [9].
  • Asset-Light Balance Sheet Profile: NIL's book value per share of Rs 62.81 [7] reflects a distribution-heavy corporate structure following prior distribution agreements with domestic pharma companies like Dr. Reddy's Laboratories [10]. Consequently, the P/B multiple (~2.6x–2.7x) primarily reflects working capital and net cash reserves (Rs 52.50 Crores cash & cash equivalents as of Q4 FY26 [11]) rather than heavy capital assets.
Valuation BasisImplied 100% Equity Value (Rs Cr)Implied Price / Share (Rs)Benchmark MetricBenchmark Value (Rs Cr)Implied Valuation MultipleCitation / Derivation Basis
SPA 70.68% Stake Consideration2,045.68828.56Q3 FY26 TTM PAT97.2321.04x P/EDerived from Rs 1,445.89 Cr SPA consideration [1] & Q3 FY26 TTM PAT [2]
SPA 70.68% Stake Consideration2,045.68828.56Q3 FY26 Book Value775.072.64x P/BDerived from Rs 1,445.89 Cr SPA consideration [1] & Q3 FY26 Equity [3]
SPA 70.68% Stake Consideration2,045.68828.56Full Year FY26 TTM PAT93.1821.95x P/EDerived from Rs 1,445.89 Cr SPA consideration [1] & FY26 TTM PAT [2]
SPA 70.68% Stake Consideration2,045.68828.56Full Year FY26 Book Value817.832.50x P/BDerived from Rs 1,445.89 Cr SPA consideration [1] & FY26 Equity [3]
Open Offer Price (Rs 860.64/sh)2,124.99860.64Q3 FY26 TTM PAT97.2321.86x P/EDerived from Rs 860.64 offer price [4], 2.47 Cr shares [1] & TTM PAT [2]
Open Offer Price (Rs 860.64/sh)2,124.99860.64Q3 FY26 Book Value775.072.74x P/BDerived from Rs 860.64 offer price [4], 2.47 Cr shares [1] & Equity [3]

What is the specific offer price per share set for the mandatory open offer under SEBI (SAST) Regulations, and how does this price compare to the volume-weighted average market price (VWAP) of the stock over the 60 days preceding the announcement?

The mandatory open offer for Novartis India Limited is set at an offer price of Rs 860.64 per share [12]. This price represents a premium over the volume-weighted average market price (VWAP) over the 60 trading days preceding the public announcement.

Pricing Details and Comparison

Analytical Context

  • Regulatory Floor Compliance: Under Regulation 8(2) of the SEBI (SAST) Regulations, the open offer price must be at least equal to the highest of several prescribed parameters, including the negotiated SPA price and the 60-day VWAP for frequently traded shares [14].
  • Valuation Alignment: The offer price of Rs 860.64 matches the highest negotiated price per share under the underlying Share Purchase Agreement (SPA) dated February 19, 2026, wherein a ChrysCapital-led consortium agreed to acquire a 70.68% controlling stake from Novartis AG [9]. Because this negotiated price (Rs 860.64) exceeds the 60-day market VWAP (Rs 803.57), it establishes the final baseline floor for public shareholders [13].
MetricAmount (INR)Source / Basis
Open Offer PriceRs 860.64Set under SEBI (SAST) Regulations for the 26% open offer [12]
60-Day VWAPRs 803.57Volume-weighted average market price for the 60 trading days preceding the February 19, 2026 Public Announcement [13]
Spread / Premium+Rs 57.07 (+7.10%)Derived premium of the offer price over the 60-day VWAP

Sources

  1. [1]Novartis India Limited: Detailed Public Statement for Open Offer by ChrysCapital Group Entities — 2026-02-26T10:46:44.120000, p.2
  2. [2]TTM PAT
  3. [3]Latest Total Equity
  4. [4]Intimation of Receipt of Letter of Offer for Mandatory Open Offer by Acquirers — 2026-06-04T14:14:45.657000, p.3
  5. [5]Novartis India: Open Offer by WaveRise, ChrysCapital, Two Infinity Partners for 26% Stake Following 70.68% Acquisition from Novartis AG. — 2026-02-19T18:59:28.897000, p.6
  6. [6]TTM EPS
  7. [7]Latest Book Value Per Share
  8. [8]Novartis India IDC Recommendation Published for Mandatory Open Offer by Acquirers at INR 860.64. — 2026-06-06T13:58:01.440000, p.2
  9. [9]Novartis India: Post-Offer Advertisement for Open Offer by WaveRise, ChrysCapital, Two Infinity; Low Acceptance. — 2026-07-10T03:25:00.750000, p.2
  10. [10]Novartis to Sell 70.68% Stake in India Unit for 14.46 Billion Rupees — Finance, 2026-02-20T00:00:00
  11. [11]Cash and Equivalents
  12. [12]Mandatory Corrigendum and Schedule Update for Novartis India Open Offer at INR 860.64 — 2026-06-11T03:01:18.910000, p.2
  13. [13]IDC Recommendation on Open Offer Price (INR 860.64) for Novartis India Takeover. — 2026-06-04T17:40:23, p.11
  14. [14]IDC Recommendation on Open Offer Price (INR 860.64) for Novartis India Takeover. — 2026-06-04T17:40:23, p.9
  15. [15]Novartis India: Annual Report FY2023-24 Submission, 76th AGM Notice, Proposed Dividend, and Board Changes — 2024-07-05T11:35:35.060000, p.43
  16. [16]Novartis India Limited: Q1 FY2026 Unaudited Financial Results and Board Meeting Outcomes — 2025-07-29T11:07:13.897000, p.3
  17. [17]TTM EBITDA Margin
  18. [18]TTM Operating Profit Margin
  19. [19]TTM Revenue INR
  20. [20]TTM EBITDA
  21. [21]TTM Other Income
  22. [22]TTM Purchases of Stock in Trade
  23. [23]TTM Capex to Revenue
  24. [24]Revenue INR YoY
  25. [25]Novartis India Q1 FY27 Unaudited Financial Results and Limited Review Report — 2026-07-23T07:34:32.013000, p.3

Keep digging

Based on the Public Announcement filed with the exchanges, what is the implied valuation multiple of the 70.68% stake acquisition compared to Novartis India’s trailing twelve-month (TTM) earnings and current book value?

Ask Copilot
Logo

Unlock financial AI for your firm

Log in